ERAS Erasca, Inc.
USHealthcareAs of 2026-10-08
Why ERAS matters now
Erasca, Inc. (ERAS) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.46 with +9.49% on the session and $5.37B in market capitalization; recent performance reads 1-month +32.46% and YTD +267.47%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-183.4M, and EPS of $-0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.1%.
The latest indexable market news headline is "Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $14.00; recent insider activity includes Garner Ebun filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
10.57
P/S
0.00
EV/EBITDA
-15.70
DCF Value
$0.10
FCF Yield
-2.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-77.0%
ROA
-60.1%
ROIC
-32.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-183.4M | $-0.60 |
| Q4 2025 | $0.00 | $-29.1M | $-0.10 |
| FY 2025 | $0.00 | $-124.5M | $-0.44 |
| Q3 2025 | $0.00 | $-30.6M | $-0.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.50
Target (Median)
$14.00
Target Range
$10.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.73
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.